arrow_back Back to App

Medicare: Enhanced Home Treatment Access for Neurological Conditions

This bill aims to expand Medicare coverage to include in-home administration of intravenous immune globulin (IVIG) for individuals with chronic neurological conditions like chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). This means patients with these conditions can receive essential treatment in the comfort of their own homes, potentially improving their quality of life and reducing the burden of clinic visits.
Key points
Starting January 1, 2026, Medicare will cover in-home IVIG administration for CIDP and MMN.
The bill allows for varying payment rates for IVIG administration based on the specific condition being treated, which may affect patient costs.
These changes are intended to improve access to treatment for patients with certain neurological diseases.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_5818
Sponsor: Rep. Smith, Adrian [R-NE-3]
Process start date: 2023-09-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Medicare IVIG Access Enhancement Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_5818.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-09-28.

What are the main provisions?

Key points include:

  • Starting January 1, 2026, Medicare will cover in-home IVIG administration for CIDP and MMN.
  • The bill allows for varying payment rates for IVIG administration based on the specific condition being treated, which may affect patient costs.
  • These changes are intended to improve access to treatment for patients with certain neurological diseases.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Smith, Adrian [R-NE-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Benefits